Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

81. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis

Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J CRD summary The authors concluded that results indicated that proton pump inhibitors therapy had potential to increase the risk of hip fracture (...) . The reliability of the authors’ conclusion is limited by potential for publication bias and the unclear quality and small number of included studies. Authors' objectives To assess the association between proton pump inhibitors therapy and hip fracture. Searching PubMed, EMBASE and The Cochrane Library were searched to June 2010 for studies in any language. Search terms were reported. Study selection Cohort and case-control studies that compared the risk of hip fractures between users of proton pump inhibitors

DARE.2011

82. Proton Pump Inhibitors 2.0

Proton Pump Inhibitors 2.0 Proton Pump Inhibitors 2.0 | Clinical Correlations Proton Pump Inhibitors 2.0 November 26, 2010 By Mary C. Whitman, MD Faculty Peer Reviewed and are prescribed to over . Recently, new data has emerged that suggests that we should be more judicious in prescribing PPIs. In a recent development, the FDA announced that it will require new labeling of PPIs indicating that their use at high . This change was prompted, in part, , who took PPIs for at least 2 years. The study (...) was a case-control, retrospective study of 33,752 patients with hip fracture and 130,471 matched controls in the Kaiser Permanente system. Among patients who had used PPIs for two or more years, there was a 30% increased risk of hip fracture compared to non-users (OR 1.30). Interestingly, the authors also indentified an increased risk of hip fracture among patients with two or more years use of H2-receptor antagonists (OR 1.18). The association between PPIs and hip fractures was positively correlated

Clinical Correlations2010

83. Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction

Clopidogrel (Plavix) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction | Clinical Correlations Clopidogrel (Plavix®) and Proton Pump Inhibitors: An Update on the Potential Drug Interaction July 28, 2010 By Antony Q. Pham, Pharm.D. and Reena M. Tejura, Pharm.D. Faculty Peer Reviewed Recent publications have described a potential drug interaction between clopidogrel (Plavix (...) ®) and proton pump inhibitors (PPIs). Several retrospective studies have concluded that the use of PPIs can lower the effectiveness of clopidogrel and as a result, increase the possibility of cardiovascular events. Limited data from prospective trials have yet to show a clinical significance from this potential interaction. The Food and Drug Administration (FDA) released an early communication about the ongoing safety review of clopidogrel and omeprazole on January 26, 2009. Over the next 10 months, the FDA worked

Clinical Correlations2010

84. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett`s esophagus

Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett`s esophagus 20188100 2010 06 10 2010 07 01 2016 11 22 1528-0012 138 7 2010 Jun Gastroenterology Gastroenterology Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. 2260-6 10.1053/j.gastro.2010.02.045 Limited evidence suggests that proton pump inhibitors (PPI), nonsteroidal anti (...) remained without EAC at the date of the EAC diagnosis for the corresponding case. We identified prescriptions for PPI, NSAIDs/aspirin, and statins that were filled between BE diagnosis and EAC diagnosis. Incidence density ratios were calculated using conditional logistic regression models that adjusted for race, outpatient encounters, a disease comorbidity index, and socioeconomic status. In a cohort of 11,823 patients with first-time BE diagnosis, we examined 116 EAC cases and 696 matched controls

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

85. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention

Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention 20538118 2010 06 11 2010 07 06 2013 11 21 1879-1913 105 12 2010 Jun 15 The American journal of cardiology Am. J. Cardiol. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. 1705-9 10.1016/j.amjcard.2010.01.348 (...) Recent studies have suggested that proton pump inhibitors (PPIs) might reduce the inhibitory effect of clopidogrel on platelet aggregation, possibly through inhibition of the hepatic cytochrome P450 2C19 (CYP2C19) isoenzyme. The prevalence of CYP2C19 loss-of-function alleles is much greater among East Asians than among other populations. Thus, potential drug interactions might be more apparent. Therefore, we conducted a nationwide, population-based study using the Taiwan National Health Insurance

EvidenceUpdates2010

86. Proton pump inhibitors and risk for recurrent Clostridium difficile infection

Proton pump inhibitors and risk for recurrent Clostridium difficile infection 20458084 2010 05 11 2010 06 02 2010 10 22 1538-3679 170 9 2010 May 10 Archives of internal medicine Arch. Intern. Med. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. 772-8 10.1001/archinternmed.2010.73 Proton pump inhibitors (PPIs) are widely used gastric acid suppressants, but they are often prescribed without clear indications and may increase risk of Clostridium difficile infection (...) (CDI). We sought to determine the association between PPI use and the risk of recurrent CDI. Retrospective, cohort study using administrative databases of the New England Veterans Healthcare System from October 1, 2003, through September 30, 2008. We identified 1166 inpatients and outpatients with metronidazole- or vancomycin hydrochloride-treated incident CDI, of whom 527 (45.2%) received oral PPIs within 14 days of diagnosis and 639 (54.8%) did not. We determined the hazard ratio (HR

EvidenceUpdates2010

87. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women`s Health Initiative

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women`s Health Initiative 20458083 2010 05 11 2010 06 02 2016 12 14 1538-3679 170 9 2010 May 10 Archives of internal medicine Arch. Intern. Med. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. 765-71 10.1001/archinternmed.2010.94 Proton pump inhibitor (PPI) medications have been (...) inconsistently shown to be associated with osteoporotic fractures. We examined the association of PPI use with bone outcomes (fracture, bone mineral density [BMD]). This prospective analysis included 161 806 postmenopausal women 50 to 79 years old, without history of hip fracture, enrolled in the Women's Health Initiative (WHI) Observational Study and Clinical Trials with a mean (SD) follow-up of 7.8 (1.6) years. Analyses were conducted for 130 487 women with complete information. Medication information

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

88. WITHDRAWN: Proton pump inhibitor treatment for acute peptic ulcer bleeding.

WITHDRAWN: Proton pump inhibitor treatment for acute peptic ulcer bleeding. BACKGROUND: Randomised controlled trials (RCTs) evaluating the clinical effect of proton pump inhibitors (PPIs) in peptic ulcer (PU) bleeding yield conflicting results. OBJECTIVES: To evaluate the efficacy of PPIs in acute bleeding from PU using evidence from RCTs. SEARCH STRATEGY: We searched CENTRAL, The Cochrane Library (Issue 4, 2004), MEDLINE (1966 to November 2004), EMBASE (1980 to November 2004), proceedings (...) of major meetings to November 2004, and reference lists of articles. We contacted pharmaceutical companies and experts in the field. SELECTION CRITERIA: RCTs of PPI treatment (oral or intravenous) compared with placebo or H(2)-receptor antagonist (H(2)RA) in acute bleeding from PU. DATA COLLECTION AND ANALYSIS: Two reviewers extracted data independently, assessed study validity, summarised studies and undertook meta-analysis. The influence of study characteristics on the outcomes was examined

Cochrane2010

89. Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial

Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial 19801933 2009 11 11 2009 12 11 2009 11 11 1528-1140 250 5 2009 Nov Annals of surgery Ann. Surg. Impact of proton pump inhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial. 667-73 10.1097/SLA.0b013e3181bcb139 The primary aim (...) of this study was to evaluate if the use of proton pump inhibitors (PPIs) reduced the prevalence of benign anastomotic strictures after uncomplicated esophagectomies with gastric tube reconstruction and circular stapled anastomoses. Benign anastomotic strictures are associated with anastomotic leaks or conduit ischemia. Also patients without those complications develop benign anastomotic strictures. We hypothesize that patients without postoperative anastomotic complications may develop benign anastomotic

EvidenceUpdates2010

90. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K CRD summary This review concluded that concomitant use (...) of proton pump inhibitors and clopidogrel might be associated with an increased risk of cardiovascular events but did not influence the risk of death in patients with established cardiovascular disease. These cautious conclusions appear appropriate, although risk of publication bias and lack of details on study quality should be borne in mind. Authors' objectives To assess whether proton pump inhibitors negatively affect clinical outcomes in patients treated with clopidogrel. Searching MEDLINE, EMBASE, Cochrane Central

DARE.2010

91. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis

The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients (...) : a meta-analysis Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB CRD summary This review found there were no differences in outcomes between treatment with proton pump inhibitors and histamine-2 receptor antagonists for critical care patients in intensive care units. The authors' cautious conclusions reflect the evidence presented, but the poor quality of the included trials and the potential for publication and language biases should be considered when interpreting the results. Authors' objectives

DARE.2010

92. High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis

High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta-analysis Wu LC, Cao YF, Huang JH, Liao C, Gao F CRD summary This generally well-conducted review concluded that the low-dose intravenous proton-pump inhibitors achieved the same efficacy as high-dose (...) proton-pump inhibitors following endoscopic haemostasis in patients with upper gastrointestinal bleeding. The authors' conclusions reflect the evidence presented, but should be interpreted with a degree of caution given the limited quality and size of most of the included trials. Authors' objectives To assess the efficacy of high-dose versus low-dose proton-pump inhibitors for the treatment of upper gastrointestinal bleeding. Searching The following databases were searched up to September 2009 without language

DARE.2010

93. Proton Pump Inhibitors for Acute Upper GI Bleeding

Proton Pump Inhibitors for Acute Upper GI Bleeding Proton Pump Inhibitors for Acute Upper GI Bleeding – TheNNTTheNNT Proton Pump Inhibitors (PPIs) Given for Acute Upper Gastrointestinal Bleeding Given Prior to Endoscopic Diagnosis No benefit found In Summary, for those who took the PPI: Benefits in NNT 100% saw no benefit 0% were helped by being saved from death, needing surgery, preventing repeat bleeding None were helped (life saved, preventing surgery, prevent repeat bleeding) Harms in NNT (...) gastrointestinal bleeding is a potentially life threatening condition that can demand aggressive intervention from the emergency physicians. Although bleeding can originate in any area above the ligament of Treitz, the majority of bleeding is from a peptic ulcer , . Proton pump inhibitors (PPIs) work by reducing gastric acid secretion, neutralizing gastric pH, increasing clot formation and decreasing clot lysis . Intravenous proton pump inhibitors have traditionally been used after endoscopic hemostasis

theNNT2010

94. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Kwok CS, Loke YK CRD summary This review found conflicting and inconsistent data on the adverse interaction between (...) clopidogrel and proton-pump inhibitors. The authors' conclusions agreed with the results of their review and appear to be appropriate. Authors' objectives To evaluate cardiovascular outcomes and mortality in patients taking clopidogrel with versus without concomitant proton-pump inhibitors. Searching MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched in October 2009, without language restrictions. The search terms were reported and a PubMed alert was set up

DARE.2010

95. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials

High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer (...) : a systematic review and meta-analysis of randomized controlled trials Wang CH, Ma MH, Chou HC, Yen ZS, Yang CW, Fang CC, Chen SC CRD summary This generally well-conducted review concluded that high-dose proton pump inhibitors did not reduce re-bleeding, surgical intervention or mortality after endoscopic treatment in patients with a bleeding peptic ulcer, compared with non-high-dose proton pump inhibitors. This conclusion is likely to be reliable. Authors' objectives To determine whether high-dose

DARE.2010

96. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia

Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia Johnstone J, Nerenberg K, Loeb M CRD summary The authors concluded that differences between included studies precluded the interpretation of the statistical significance of the association between proton pump inhibitor use and the risk (...) of community-acquired pneumonia. The authors’ cautions conclusions reflect evidence from potentially biased observations studies. Authors' objectives To evaluate the association between the use of proton pump inhibitors and community-acquired pneumonia in adults. Searching MEDLINE, EMBASE and CINAHL were searched from inception to January 2010 for studies published after 1988 (the year proton pump inhibitors were introduced). Search terms were reported. Reference lists of articles were screened. Reports

DARE.2010

97. Clopidogrel and proton pump inhibitors: interaction?updated advice

Clopidogrel and proton pump inhibitors: interaction?updated advice Clopidogrel and proton pump inhibitors: interaction—updated advice Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Clopidogrel and proton pump inhibitors: interaction—updated advice From: Published: 1 April 2010 Therapeutic area: and In light of the most recent evidence, the previous advice on the concomitant use of clopidogrel with proton pump inhibitors has now been modified. Use of either (...) omeprazole or esomeprazole with clopidogrel should be discouraged. The current evidence does not support extending this advice to other PPIs Article date: April 2010 Clopidogrel is indicated for the prevention of atherothrombotic events in patients who have had a myocardial infarction or ischaemic stroke, or who have established peripheral arterial disease. Combined with aspirin, the brand leader product (Plavix) may also be used to prevent atherothrombotic events in patients with acute coronary syndrome

MHRA Drug Safety Update2010

98. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID

ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID nature publishing group the red section 2533 Writing Committee Members Neena S. Abraham, MD, FACG, Chair*; Mark A. Hlatky, MD, FACC, FAHA, Vice Chair† Elliott M. Antman, MD, FACC, FAHA‡; Deepak L. Bhatt, MD, MPH, FACC, FAHA† David J. Bjorkman (...) KW , Quigley EM, Scheiman J, Sper - ling LS, Tomaselli GF (. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533–2549; doi:10.1038/ajg.2010.445. This article has been copublished in the Journal of the American College of Cardiology and Circulation. Copies

American College of Gastroenterology2010

100. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease

Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease 19392864 2009 05 27 2010 02 22 2009 05 27 1365-2036 29 12 2009 Jun 15 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. 1261-72 10.1111/j.1365-2036.2009.04013.x (...) The proportion of patients who respond to proton pump inhibitor (PPI) therapy is about 20% lower in those with non-erosive reflux disease (NERD) than in those with erosive oesophagitis. To assess efficacy and safety of dexlansoprazole MR, a PPI using Dual Delayed Release technology, in NERD patients. In this 4-week, double-blind, placebo-controlled study, 947 NERD patients randomly received dexlansoprazole MR 30 mg, 60 mg or placebo once daily (QD). The percentages of 24-h heartburn-free days (primary

EvidenceUpdates2009